These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. Benson TJ; McKie JH; Garforth J; Borges A; Fairlamb AH; Douglas KT Biochem J; 1992 Aug; 286 ( Pt 1)(Pt 1):9-11. PubMed ID: 1355650 [TBL] [Abstract][Full Text] [Related]
7. Molecular studies on trypanothione reductase, a target for antiparasitic drugs. Walsh C; Bradley M; Nadeau K Trends Biochem Sci; 1991 Aug; 16(8):305-9. PubMed ID: 1957352 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of substrate analogue inhibitors of trypanothione reductase. Duyzend MH; Clark CT; Simmons SL; Johnson WB; Larson AM; Leconte AM; Wills AW; Ginder-Vogel M; Wilhelm AK; Czechowicz JA; Alberg DG J Enzyme Inhib Med Chem; 2012 Dec; 27(6):784-94. PubMed ID: 22085139 [TBL] [Abstract][Full Text] [Related]
9. Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Hamilton CJ; Saravanamuthu A; Eggleston IM; Fairlamb AH Biochem J; 2003 Feb; 369(Pt 3):529-37. PubMed ID: 12416994 [TBL] [Abstract][Full Text] [Related]
10. Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: potential rational drug design lead frameworks. McKie JH; Garforth J; Jaouhari R; Chan C; Yin H; Besheya T; Fairlamb AH; Douglas KT Amino Acids; 2001; 20(2):145-53. PubMed ID: 11332449 [TBL] [Abstract][Full Text] [Related]
11. Trypanothione reductase from the human parasite Entamoeba histolytica: a new drug target. Tamayo EM; Iturbe A; Hernández E; Hurtado G; de Lourdes Gutiérrez-X M; Rosales JL; Woolery M; Ondarza RN Biotechnol Appl Biochem; 2005 Apr; 41(Pt 2):105-15. PubMed ID: 15157186 [TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of inhibitors of the trypanothione cycle. D'Silva C; Daunes S Expert Opin Investig Drugs; 2002 Feb; 11(2):217-31. PubMed ID: 11829713 [TBL] [Abstract][Full Text] [Related]
13. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs. Colotti G; Baiocco P; Fiorillo A; Boffi A; Poser E; Chiaro FD; Ilari A Future Med Chem; 2013 Oct; 5(15):1861-75. PubMed ID: 24144416 [TBL] [Abstract][Full Text] [Related]
14. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Fairlamb AH; Henderson GB; Cerami A Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2607-11. PubMed ID: 2704738 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. Aguirre G; Cabrera E; Cerecetto H; Di Maio R; González M; Seoane G; Duffaut A; Denicola A; Gil MJ; Martínez-Merino V Eur J Med Chem; 2004 May; 39(5):421-31. PubMed ID: 15110968 [TBL] [Abstract][Full Text] [Related]
16. Engineering the substrate specificity of glutathione reductase toward that of trypanothione reduction. Henderson GB; Murgolo NJ; Kuriyan J; Osapay K; Kominos D; Berry A; Scrutton NS; Hinchliffe NW; Perham RN; Cerami A Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8769-73. PubMed ID: 1924337 [TBL] [Abstract][Full Text] [Related]
17. Redox enzyme engineering: conversion of human glutathione reductase into a trypanothione reductase. Bradley M; Bücheler US; Walsh CT Biochemistry; 1991 Jun; 30(25):6124-7. PubMed ID: 2059620 [TBL] [Abstract][Full Text] [Related]